Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 323

Similar articles for PubMed (Select 21854540)

1.

Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.

Harmsze AM, van Werkum JW, Souverein PC, Breet NJ, Bouman HJ, Hackeng CM, Ruven HJ, ten Berg JM, Klungel OH, de Boer A, Deneer VH.

J Thromb Haemost. 2011 Oct;9(10):1892-901. doi: 10.1111/j.1538-7836.2011.04483.x.

PMID:
21854540
2.

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM.

Heart. 2011 Aug;97(15):1239-44. doi: 10.1136/hrt.2010.220509. Epub 2011 May 31.

PMID:
21628721
3.

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.

PMID:
19934793
4.

The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.

Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM, Ruven HJ, Klungel OH, de Boer A, Deneer VH.

Thromb Haemost. 2010 May;103(5):920-5. doi: 10.1160/TH09-08-0516. Epub 2010 Mar 29.

PMID:
20352154
5.

High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.

Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, ten Berg JM.

Heart. 2011 Jun;97(12):983-90. doi: 10.1136/hrt.2010.220491. Epub 2011 Apr 8.

PMID:
21478385
6.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
7.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

8.

Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.

Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA.

Circ Cardiovasc Interv. 2011 Dec 1;4(6):585-94. doi: 10.1161/CIRCINTERVENTIONS.111.962555. Epub 2011 Nov 1.

9.

The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

J Cardiovasc Pharmacol. 2010 Nov;56(5):532-9. doi: 10.1097/FJC.0b013e3181f68209.

PMID:
20729752
10.

Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Heart. 2010 Feb;96(3):186-9. doi: 10.1136/hrt.2009.171488. Epub 2009 Aug 16.

PMID:
19687016
11.

Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.

Thromb Res. 2009 May;124(1):46-51. doi: 10.1016/j.thromres.2008.10.007. Epub 2008 Nov 28.

PMID:
19041120
12.

The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW.

Thromb Res. 2011 Oct;128(4):352-7. doi: 10.1016/j.thromres.2011.05.008. Epub 2011 May 28.

PMID:
21621250
13.
14.

Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.

Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G.

J Am Coll Cardiol. 2011 Nov 1;58(19):1945-54. doi: 10.1016/j.jacc.2011.06.059.

15.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

16.

Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.

Tentzeris I, Jarai R, Farhan S, Brozovic I, Smetana P, Geppert A, Wojta J, Siller-Matula J, Huber K.

Thromb Haemost. 2010 Dec;104(6):1211-8. doi: 10.1160/TH10-04-0218. Epub 2010 Oct 12.

PMID:
20941464
17.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

18.

Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.

Sarafoff N, Sibbing D, Sonntag U, Ellert J, Schulz S, Byrne RA, Mehilli J, Schömig A, Kastrati A.

Thromb Haemost. 2010 Sep;104(3):626-32. doi: 10.1160/TH09-11-0800. Epub 2010 Jul 20.

PMID:
20664905
19.

Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.

Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N.

Circulation. 2011 Feb 8;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640. Epub 2011 Jan 24.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk